An overview of seventeen years of experience with dothiepin in the treatment of depression in Europe.
The European clinical experience with dothiepin since 1962 indicates that it is efficacious in the treatment of depression (neurotic, psychotic, and with concomitant anxiety) in dose of 75-200 mg/day. The side effects profile is similar to the tricyclic antidepressant drugs with significantly less anticholinergic side effects and cardiotoxicity then amitriptyline. The result of the current ongoing clinical trails in the United States with several hundred patients will more precisely define the efficacy, dosage and side effect profile of dothiepin.
D000293:Adolescent; D000328:Adult; D000341:Affective Disorders, Psychotic / Q000188:drug therapy; D000368:Aged; D001008:Anxiety Disorders / Q000188:drug therapy; D003866:Depressive Disorder / Q000188:drug therapy*; D003988:Dibenzothiepins / Q000627:therapeutic use*; D004308:Dothiepin / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D003988:Dibenzothiepins; D004308:Dothiepin